Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MBX Biosciences, Inc. Common Stock (MBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MBX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $59
1 Year Target Price $59
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.62% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 615.73M USD | Price to earnings Ratio - | 1Y Target Price 59 |
Price to earnings Ratio - | 1Y Target Price 59 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 4.81 - 27.50 | Updated Date 10/17/2025 |
52 Weeks Range 4.81 - 27.50 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.75% | Return on Equity (TTM) -56.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 524728591 | Price to Sales(TTM) - |
Enterprise Value 524728591 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 44715498 | Shares Floating 22080240 |
Shares Outstanding 44715498 | Shares Floating 22080240 | ||
Percent Insiders 2.33 | Percent Institutions 86.51 |
Upturn AI SWOT
MBX Biosciences, Inc. Common Stock
Company Overview
History and Background
MBX Biosciences is a clinical stage biopharmaceutical company pioneering Precision Endocrine Peptide (PEP) therapeutics to treat endocrine disorders. Founded to advance research and development of novel peptide therapeutics, they focus on rare endocrine diseases. More information than this is not available in public sources.
Core Business Areas
- PEP Therapeutics Development: Development of Precision Endocrine Peptide (PEP) therapeutics for endocrine disorders.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their PEP therapeutics.
- Research and Development: Focus on research and innovation in peptide-based therapies targeting specific endocrine pathways.
Leadership and Structure
Information regarding the leadership team and organizational structure is limited in readily available public sources.
Top Products and Market Share
Key Offerings
- MBX 2147 (Hypoparathyroidism): A long-acting PTH1 receptor agonist designed to address the limitations of current hypoparathyroidism treatments. Currently in clinical trials. Market share data is unavailable at this stage of development. Competitors include Ascendis Pharma (TransCon PTH) and Takeda (Natpara).
Market Dynamics
Industry Overview
The biopharmaceutical industry is rapidly evolving, with increasing focus on precision medicine and targeted therapies. The endocrine disease market is driven by unmet needs in rare and chronic conditions.
Positioning
MBX Biosciences is positioned as an innovator in PEP therapeutics, with a focus on developing best-in-class treatments for endocrine disorders. Their competitive advantage lies in their proprietary PEP technology platform.
Total Addressable Market (TAM)
The global endocrine disorder market is estimated at billions of dollars. MBX Biosciences is targeting specific segments within this market, particularly hypoparathyroidism, with significant growth potential. Specific TAM estimate not available.
Upturn SWOT Analysis
Strengths
- Proprietary Precision Endocrine Peptide (PEP) technology platform
- Focus on rare endocrine diseases with unmet medical needs
- Experienced scientific team
- Strong intellectual property position
Weaknesses
- Early-stage company with limited commercialized products
- Reliance on successful clinical trial outcomes
- Dependence on funding and partnerships
- Concentrated pipeline targeting specific indications
Opportunities
- Expanding the pipeline to address other endocrine disorders
- Partnering with larger pharmaceutical companies for commercialization
- Securing regulatory approvals for lead product candidates
- Leveraging PEP technology for other therapeutic areas
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles and delays
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- Ascendis Pharma (ASND)
- Takeda (TAK)
- Amgen (AMGN)
Competitive Landscape
MBX Biosciences competes with established pharmaceutical companies and emerging biotech firms in the endocrine disease market. Their PEP technology offers a differentiated approach compared to existing therapies. Specific market share is not yet established.
Growth Trajectory and Initiatives
Historical Growth: Since the company is private, this data is not readily accessible.
Future Projections: Future growth is contingent upon successful clinical trial results and potential partnerships. Analyst estimates are unavailable.
Recent Initiatives: Focusing on advancing MBX 2147 through clinical development and expanding their pipeline of PEP therapeutics.
Summary
MBX Biosciences is an early-stage biopharmaceutical company with a promising technology platform focused on developing innovative peptide therapies for endocrine disorders. Their success is heavily reliant on positive clinical trial results for their lead product candidate and securing future funding. Competition in the endocrine market is intense, but their PEP technology offers a potentially differentiated approach. Further market access and analysis will depend on available sources once the company becomes public.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MBX Biosciences website
- Industry reports and press releases
- ClinicalTrials.gov
Disclaimers:
The information provided is based on publicly available data and should not be considered financial advice. The analysis is subject to change based on new information. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MBX Biosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Carmel, IN, United States | ||
IPO Launch date 2024-09-13 | CEO, President & Director Mr. Peter Kent Hawryluk MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://mbxbio.com |
Full time employees 43 | Website https://mbxbio.com | ||
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.